RYBREVANT VIVZA
Live / Applied — First extension granted (statement of use) (as of 08 Sept 2025)
What this means for you
Not registered yet, but its 15 Aug 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98648760
- Mark type
- Stylized text
- Filed
- 15 Aug 2024
- Published for opposition
- 04 Feb 2025
- Attorney of record
- Cheryl L. Foytlin
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations for the treatment of oncological diseases and disorders
Owner
- Johnson & Johnson, New Brunswick, NJ, US
- Johnson & Johnson, New Brunswick, NJ, US
Prior registrations
Prosecution history
- 15 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 08 Sept 2025 — SOU EXTENSION 1 GRANTED
- 08 Sept 2025 — SOU EXTENSION 1 FILED
- 08 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 01 Apr 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 04 Feb 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 04 Feb 2025 — PUBLISHED FOR OPPOSITION
- 29 Jan 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 15 Jan 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 14 Jan 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 14 Jan 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 14 Jan 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED
- 19 Nov 2024 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 19 Nov 2024 — NON-FINAL ACTION E-MAILED
- 19 Nov 2024 — NON-FINAL ACTION WRITTEN